Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190122 | 0.78 | MAPK1 (0.47) | LMNAMAPK1GAAKDM4EALDH1A1 | |
| SCHEMBL1087300 | 0.72 | NOS3 (0.37) | ALDH1A1MAPTKMT2ANOS3NOS1 | |
| SCHEMBL14411458 | 0.70 | MAPK1 (0.44) | LMNAMAPK1GAAKDM4EALDH1A1 | |
| SCHEMBL4085470 | 0.69 | NOS3 (0.34) | ALDH1A1MAPTNOS3NOS1NOS2 | |
| SCHEMBL24672233 | 0.67 | GABRA1 (0.41) | GAAKDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL31092533 | 0.67 | GABRA1 (0.41) | GAAKDM4EALDH1A1NOS3NOS1 | |
| SCHEMBL27942432 | 0.67 | ALDH1A1 (0.47) | ALDH1A1MAPTNOS3NOS1NOS2 | |
| SCHEMBL11313945 | 0.67 | LMNA (0.35) | LMNAGAAKDM4EALDH1A1MAPT | |
| SCHEMBL9770020 | 0.66 | GRIN2D (0.43) | MAPK1ALDH1A1MAPTKMT2ANOS3 | |
| SCHEMBL14156225 | 0.66 | MAPK1 (0.36) | MAPK1GAAKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152047-A1 | BENZAMIDE DERIVATIVE | CYP3A5, HDAC6, BRD1 | LMNA 3150/4885MAPK1 3917/4885GAA 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.